The US Food and Drug Administration has approved two new indications for the osteoporosis drug, Prolia (denosumab), enabling it to be used for cancer treatment-induced bone loss, according to Amgen Inc, the developer. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News